Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have as
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One analyst h… [+3481 chars]